News Gilead trumpets data with newly-bought magrolimab in blood c... Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.
Views & Analysis Surviving COVID-19 as a bone marrow transplant patient Jayne Snell is one of the 1.5 million people in the UK to receive a letter asking them to stay at home for three months in a bid to avoid COVID-19.
News Gilead to buy immuno-oncology firm Forty Seven for $4.9bn Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends